PubMed Health⌕ Search

Biomedical subjects

M A Aziz

Publications and source records attributed to M A Aziz.

72 records · Page 4Linked to original sources
PubMed1968

Marchezani syndrome.

Explore the source record for details and available documents.

Abnormalities, Multiple↗
PubMedDate not supplied

Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

The clinical experience of 1,723 patients treated with imipenem/cilastatin in worldwide clinical trials is reviewed. Dosages of imipenem administered parenterally with cilastatin varied with the severity of the infection and included 250 mg four times a day; 500 mg three or four times a day, and 1 g three of four times a day. Infections of all body systems except the central nervous system due to gram-positive or gram-negative aerobes and anaerobes as well as those due to mixed organisms were treated. Clinical efficacy was demonstrated in 92% of infections. The adverse clinical and laboratory experiences associated with imipenem/cilastatin were similar to those of other beta-lactam agents and included disturbances of gastrointestinal and central nervous system function, allergic reactions, and transient elevations of liver enzyme levels.

Adult↗
PubMedDate not supplied

Chemotherapeutic approach to control of onchocerciasis.

Onchocerciasis is one of the leading causes of blindness in the developing world. An estimated 40 million people are afflicted with this parasitic disease. World Health Organization vector control programs have had considerable success in interrupting the parasite transmission cycle in selected savanna regions of West Africa, but chemotherapeutic agents suitable for massive treatment campaigns have not been available. Controlled clinical studies have indicated that a single oral dose of ivermectin is safer and more effective therapy for onchocerciasis than the the standard seven- to 10-day course of diethylcarbamazine, the current drug of choice, and that ivermectin causes a more prolonged reduction in dermal microfilarial density. Patients treated with ivermectin are unable to infect the blackfly vector as long as the dermal microfilarial density remains low; therefore, once- or twice-yearly administration of ivermectin in community-wide therapy programs, either alone or in combination with vector control measures, may successfully interrupt transmission of the parasite and eventually eliminate the disease.

Administration, Oral↗